Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... global antibiotic resistance problem  MGB Biopharma, ... of anti-infectives, to address the major global problem ... developed a stable intravenous (IV) formulation of MGB-BP-3, designed ... Gram-positive hospital-acquired infections.  The intravenous formulation of ...
(Date:6/2/2015)... LA (PRWEB) June 02, 2015 ... gene synthesis to improve protein expression, announced the formation ... includes six executives and entrepreneurs with a broad range ... industries. , The team includes: , Jimmy Roussel, ... , Roussel has a background in technology and marketing. ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
Breaking Biology Technology:MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3
... CHENGDU, China , June 3 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. (NYSE ... the updated corporate presentation at the Company,s website: , , ... http://www.tianyinpharma.com , , , ... , , ...
... June 2 Caliper Life Sciences, Inc. (Nasdaq: CALP ... Sciences Conference, will be webcast on Friday, June 11 at ... will be providing an update on the company,s business. The live webcast ... available for 90 days. , , ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin ... at the Jefferies 2010 Global Life Sciences Conference and also at the 9th ... , , ... place on Wednesday, June 9, 2010 at 1:30 p.m. Eastern ...
Cached Biology Technology:Tianyin Corporate Presentation Updated 2Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference 2
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... A research paper co-written by a Virginia Tech faculty ... nose that is unusually large for its species. The ... journal, Physical Review Letters . The article, ... morphology," by Z. Zhang, R. Mller, and S.N. Truong, ...
... have a clear agenda when it comes to selecting a ... and preferring large females, they are likely to have more ... Beat Mattle and Tony Wilson from the Zoological Museum at ... have just been published online in Springer,s journal Behavioral ...
... of Interventional Radiology 2009 Standards Division Guidelines" is ... July issue of the Journal of Vascular ... physicians, scientists and allied health professionals dedicated to ... invasive, image-guided therapeutic interventionsprovides a unique collection of ...
Cached Biology News:Mystery of bat with an extraordinary nose solved 2Male seahorses like big mates 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 3
Request Info...
... The Light Diagnostics Cytomegalovirus (CMV) pp65 Antigenemia ... qualitative identification of lower matrix protein pp65 ... Kit Components: ... One bottle containing 220 mL of buffered ...
CHIMAERIC HUMAN IgA2 ANTI NP...
... suspension (non-adherent) cells, RNA ture ... or centrifugation to separate cells ... with 96-well GenePlate®. RiboCap™ plates ... sizes and contain the appropriate ...
Biology Products: